Results 221 to 230 of about 5,808 (257)

Quantitative Pharmacology Methods for Bispecific T Cell Engagers

Bulletin of Mathematical Biology
Abstract T Cell Engager (TCE)s are an exciting therapeutic modality in immuno-oncology that acts to bypass antigen presentation and forms a direct link between cancer and immune cells in the Tumor Microenvironment (TME). TCEs are efficacious only when the drug is bound to both immune and cancer cell targets.
Mahdiar Sadeghi, Irina Kareva, Gleb Pogudin, Eduardo D. Sontag   +3 more
openaire   +2 more sources

Clinical Experience with Bispecific T Cell Engagers

2019
Bispecific T cell engagers are antibody constructs directed to a tumor-specific target on the one hand and to CD3-positive T cells on the other hand. Blinatumomab is a compound with specificity for the pan-B cell marker CD19. Clinical activity was tested in relapsed and refractory (R/R) non-Hodgkin's Lymphoma (NHL), R/R acute lymphoblastic leukemia ...
openaire   +2 more sources

Bispecific antibodies engage T cells for antitumor immunotherapy

Expert Opinion on Biological Therapy, 2011
Although considerable evidence supports the hypothesis that T cells play a critical role in the immune response against cancer, the ability to mount and sustain tumor-specific cellular responses in vivo remains a challenge. A strategy that harnesses the cytotoxic advantage of T cell therapy is the use of bispecific antibodies designed to engage and ...
Bryan D, Choi, Mingqing, Cai, Darell D, Bigner, Ankit I, Mehta, Chien-Tsun, Kuan, John H, Sampson   +5 more
openaire   +2 more sources

Blinatumomab: A novel, bispecific, T-cell engaging antibody

American Journal of Health-System Pharmacy, 2016
The pharmacology, pharmacodynamics, pharmacokinetics, efficacy in clinical trials, safety and tolerability, and place in therapy of blinatumomab are reviewed.Blinatumomab is a novel, bispecific, T-cell engaging antibody that targets tumor-associated antigens CD19 and CD3.
Megan Brafford, May, Ashley, Glode
openaire   +2 more sources

Myeloma evades T cell-engaging therapies

Nature Cancer, 2023
Bruno Paiva, Jesús F. San-Miguel
openaire   +2 more sources

T cell receptor engagement can influence T cell motility

Transplantation Proceedings, 2001
Marelli-Berg, F M, Alvarez-Iglesias, M, Prodromidou, K, Lombardi, G, Frasca, L, Berg, L P, Lechler, R I   +6 more
openaire   +3 more sources

TRISPECIFIC T CELL ENGAGERS

2021
KAROW MARGARET, YAU RICHARD, SHENG JACKIE   +2 more
openaire   +4 more sources

Bispecific T cell engagers

2021
KAROW MARGARET, YAU RICHARD, SHENG JACKIE   +2 more
openaire   +4 more sources

Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas

Future Oncology, 2022
Valentina Gambardella, Martin Wermke, Taofeek Owonikoko   +2 more
exaly  

Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody

Frontiers in Immunology, 2023
Harald Kolmar, Julius Grzeschik, Björn Hock   +2 more
exaly